Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-PEG2-RM26 PET/CT in GRPR-Overexpressing Cancers
NCT06147362Phase 1Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NOTA-RM26 in prostate cancer (PCa), breast cancer, colorectal cancer (CRC) and 3 more, sponsored by Karolinska University Hospital. Primary endpoint: Adverse events within 2 weeks of injection. Started Jun 2022; status: recruiting.
02
Drugs
68Ga-NOTA-RM26
03
Conditions
prostate cancer (PCa)breast cancercolorectal cancer (CRC)gastrointestinal carcinoid tumorgastric cancer (GC)
Beyond the preview
Go deeper on NCT06147362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147362.